CriticalAntiviral for systemic use, HIV-1 protease inhibitor; used only with a pharmacokinetic booster (ritonavir or cobicistat)×Selective If channel inhibitor of the sinoatrial node
Updated · Methodology
Mechanism
Only the enzyme CYP3A4 metabolises ivabradine in the liver, so inhibitors of this enzyme raise its levels. The strong inhibitors ketoconazole and josamycin increased mean ivabradine exposure 7- to 8-fold (ivabradine summary of product characteristics, SmPC, European Medicines Agency, EMA). High ivabradine levels may cause excessive slowing of the heart rate (ivabradine SmPC, EMA). Darunavir is taken only with a booster (ritonavir or cobicistat), and in this regimen it slows the clearance of drugs that depend heavily on CYP3A (darunavir SmPC, EMA). The pair has not been studied, but the darunavir documents expect ivabradine levels to rise (darunavir SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; darunavir label, US Food and Drug Administration, FDA). Ivabradine itself is a very weak CYP3A4 inhibitor and does not affect the metabolism of other CYP3A4 substrates (ivabradine SmPC, EMA).
Symptoms
Excess ivabradine may cause severe and prolonged slowing of the heart rate, or bradycardia (ivabradine summary of product characteristics, SmPC, European Medicines Agency, EMA). Sinus arrest and heart block have also occurred during ivabradine treatment (ivabradine label, US Food and Drug Administration, FDA). Bradycardia may show as dizziness, fatigue or low blood pressure (ivabradine SmPC, EMA). Bradycardia may increase the risk of QT prolongation on the electrocardiogram (ECG). This may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients taking QT-prolonging drugs (ivabradine FDA label).
Management
The combination is contraindicated. Ivabradine is on the darunavir contraindication list with either booster (ritonavir or cobicistat), including the fixed-dose darunavir/cobicistat tablet (darunavir and darunavir/cobicistat summaries of product characteristics, SmPCs, European Medicines Agency, EMA; darunavir SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US labels of darunavir with ritonavir and with cobicistat also contraindicate ivabradine (darunavir labels, US Food and Drug Administration, FDA). The ivabradine documents contraindicate strong CYP3A4 inhibitors and give human immunodeficiency virus (HIV) protease inhibitors as an example. The European SmPC names nelfinavir and ritonavir, so in a ritonavir-boosted darunavir regimen the booster itself is contraindicated with ivabradine (ivabradine SmPC, EMA; ivabradine FDA label). Before and during darunavir treatment, review all concomitant medicines for interactions (darunavir FDA label). If ivabradine and darunavir have nevertheless been taken together and severe bradycardia develops, consider symptomatic treatment in a specialised setting. If bradycardia is poorly tolerated, this may include an intravenous beta-stimulant such as isoprenaline, and temporary cardiac pacing if needed (ivabradine SmPC, EMA). The US label also mentions intravenous fluids and atropine (ivabradine FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Prezista (darunavir) prescribing information (2025)– FDA, DailyMed, setid 814301f9-c990-46a5-b481-2879a521a16f, SPL 08/2025 (Revised 03/2023), sections 4 and 7 (Table 10)
- EMA: Ficha técnica: Ivabradina – Procoralan (EU/1/05/316), sección 4.3 (2025)– EMA, SmPC Procoralan (EU/1/05/316), texto en CIMA nº 05316003, información del producto actualizada 17/11/2025, secciones 4.3, 4.4 y 4.5
- FDA: Corlanor (ivabradine) prescribing information (2025)– FDA, DailyMed, Amgen, setid 92018a65-38f6-45f7-91d4-a34921b81d0d, v33, 11/2025, sections 2.1, 4, 5.3, 7.1 and 7.2
- EMA: Ficha técnica: Darunavir (Prezista, EU/1/06/380), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 106380007 (EU/1/06/380), secciones 4.3 y 4.5, consultado 10/2026
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.5 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Darunavir (Darunavir Aurovitas, nº registro 84835), sección 4.5 (2023)– AEMPS, CIMA, nº registro 84835, revisión 09/2023, secciones 4.3 y 4.5
- FDA: PREZCOBIX (darunavir and cobicistat) prescribing information (2026)– FDA, DailyMed setid 9c38fdb6-d0ba-4f16-a0e3-85d9ec334d9f (Janssen Products), revisión 02/2026 (versión 29), secciones 4, 6.2, 7.1 y 7.3